Position
Compound Planning, Inc. in Regeneron Pharmaceuticals, Inc.
Back to the book · All holders of REGN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $1.3K$772.22 → $773.00
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 1.68K | $1.29M | — | — | — | 0.0% |
| Q1 2026 | 1.81K | $1.4M | $773.00 | $1.3K | $104.4K | 0.0% |